Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 155-157

  Stittelaar, Koert J ^a,b   Vos, Helma W ^a   Van Amerongen, Geert ^b   Kersten, Gideon F A ^b   Osterhaus, Albert D M E ^a   De Swart, Rik L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Iscom; Measles; Quil A

Indexed keywords

GAMMA INTERFERON; ISCOM; MEASLES VACCINE; NEUTRALIZING ANTIBODY; QUIL A; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; SAPONIN; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; FOLLOW UP; MACACA; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS INACTIVATION; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MEASLES; PHYSIOLOGY; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; LYMPHOCYTE ACTIVATION; MEASLES; MEASLES VACCINE; MEASLES VIRUS; SAPONINS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL FUSION PROTEINS;

EID: 0037073568     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00453-X     Document Type: Article

References (11)

1. Osterhaus A.D.M.E., van Amerongen G., Van Binnendijk R.S. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine. 16:1998;1479-1481.
2. Clements C.J., Cutts F.T. The epidemiology of measles: 30 years of vaccination. Curr. Top. Microbiol. Immunol. 191:1995;13-33.
3. Van Binnendijk R.S., Poelen M.C.M., van Amerongen G., De Vries P., Osterhaus A.D.M.E. Protective immunity in macaques vaccinated with live attenuated, recombinant and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:1997;524-534.
4. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G.et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles vaccine in the presence of passively acquired antibodies. J. Virol. 74:2000;4236-4243.
5. Ronnberg B., Fekadu M., Behboudi S., Kenne L., Morein B. Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity. Vaccine. 15:1997;1820-1826.
6. Sjolander A., Drane D., Maraskovsky E., Scheerlinck J.P., Suhrbier A., Tennent J.et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine. 19:2001;2661-2665.
7. Kamstrup S., San Martin R., Doberti A., Grande H., Dalsgaard K. Preparation and characterisation of Quillaja saponin with less heterogeneity than Quil A. Vaccine. 18:2000;2244-2249.
8. Stittelaar K.J., Boes J., Kersten G.F.A., Spiekstra A., Mulder P.G.H., De Vries P.et al. In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine. 18:2000;2482-2493.
9. Wyde P.R., Stittelaar K.J., Osterhaus A., Guzman E., Gilbert B.E. Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine. 19:2000;42-53.
10. Fulginiti V.A., Eller J.J., Downie A.W., Kempe C.H. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated virus vaccines. J. Am. Med. Assoc. 202:1967;1075-1080.
11. Polack F.P., Auwaerter P.G., Lee S.H., Nousari H.C., Valsamakis A., Leiferman K.M.et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:1999;629-634.